hotspot -WSS

hotspot

author：hotspot 2025-09-27 12:58:11 - browse：955

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： How climate

focus

hotspot

WSS

It's time to take a new tack for treating Alzheimer's

The EU Joint Clinical Assessment needs to live up to its promise

Why Marc Tessier

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

UnitedHealth’s board chair also owns a personal investment firm

Senate committee scrutinizes Medicare Advantage brokers

knowledge

hotspot

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

Pfizer's RSV vaccine recommended for approval in Europe

23andMe had bad news about my health. I wish a person had delivered it

Pfizer's RSV vaccine recommended for approval in Europe

Medicare proposal to cover medical devices draws a mixed reaction

Florida babysitter arrested over hot car death, authorities say

The cancer drug shortage isn’t new — and neither are the solutions

How climate

Walensky prepares to leave CDC — and Congress — behind

2023 STAT Wunderkinds: get to know the winners

explore

Researchers explore possible ties between long Covid, menopause

A former Republican legislative candidate has been charged for his role in the US Capitol riot

UnitedHealth’s board chair also owns a personal investment firm

STAT Summit: GSK CEO on pharma giant's new direction

Pfizer's RSV vaccine recommended for approval in Europe

STAT Summit: Michael J. Fox on progress in Parkinson's research

focus

Wikipedia

hotspot

explore